We read with interest the recent paper by Choi et al(1) on the impact of biopsy-proven NASH on CHB outcomes. The study concluded that compared to patients with CHB alone, CHB patients with concomitant NASH were more likely to have advanced fibrosis (F3/4) and shorter time to liver complications, and that superimposed NASH predicted poorer outcomes in those with advanced fibrosis. However, prior studies have also suggested that CHB patients with co-existing hepatic steatosis may not be at higher risk for disease progression; and in fact, more favorable long-term outcomes were even reported by some.
View details for DOI 10.1002/hep.30983
View details for PubMedID 31595532